Reuters Market Eye - Shares in Glenmark Pharmaceuticals (GLEN.NS) gain 2.5 percent after U.S. health regulators approved Salix Pharmaceuticals Ltd's SLXP.O drug to treat diarrhoea in HIV/AIDS patients on qantiretroviral therapy, a combination of medicines used to treat HIV infection.
Glenmark will be the active pharmaceutical ingredients supplier for the drug to Salix in regulated markets.
An international arbitrator ruled in August 2012 that Glenmark Pharmaceuticals has the right to sell its HIV-associated diarrhoea drug Crofelemer in 140 countries.
Edelweiss in a report says, "The overall potential market for Crofelemer is anticipated at $300 million-$500 million and peak potential revenue for Glenmark, from API supply, could be $15 million-$20 million per annum."
(Reporting by Abhishek Vishnoi)
Glencore speeds up debt reduction with Australian copper mine deal
MELBOURNE Glencore Plc has agreed to sell all the gold and a 30 percent stake in its Ernest Henry copper mine in Australia to Evolution Mining for A$880 million ($670 million), advancing the Swiss giant's effort to pay down debt.
Gold steady as investors await U.S. rate hike clues
Gold was trading in a narrow range on Wednesday as investors waited for clues on whether the U.S. Federal Reserve would hike interest rates this year.
Asian stocks slip on profit-taking; oil falls
HONG KONG Asian stocks edged lower on Wednesday as strong U.S housing data overnight increased the chances of an interest rate increase in coming months, prompting some investors to take profits, while oil prices slipped after a surprise jump in U.S. inventories.